Elisabeth Schwartz | Senior Director of Investor Relations |
John Thero | President and Chief Executive Officer |
Mike Kalb | Chief Financial Officer |
Aaron Berg | Chief Commercial Office |
Michael Yee | Jefferies |
Yasmeen Rahimi | Roth Capital |
Louise Chen | Cantor Fitzgerald |
Paul Choi | Goldman Sachs |
Welcome to Amarin Corporation’s Conference Call to discuss its financial and operating results for the Fourth Quarter and Full Year of 2019. This conference call is being recorded today, February 25, 2020. I would now turn the conference call over to Elisabeth Schwartz, Senior Director of Investor Relations of Amarin.
Please be aware that this conference call will contain forward looking statements that are intended to be covered under the Safe Harbor provided by the Private Securities Litigation Reform Act. Examples of such statements include, but are not limited to, our current expectations regarding our commercial and financial performance, including levels of receipt for prescription, receipt of product and licensing revenues, cost and other commercial metrics, gross margin expenditures, such as for the purchase of additional supply of VASCEPA and the adequacy of our financial resources, our current expectations for additional scientific presentations, publications, medical guidelines and regulatory reviews outside the United States and related timing thereof, our plan and preparation for expanded promotion of VASCEPA and related market positioning potential, including the potential for further product development, our goals regarding the timing, scope and success with international expansion, our current plans for sales force and other commercial expansion in the United States and our current expectations regarding the outcome of litigation pertaining to VASCEPA exclusivity in United States.